欧洲神经内分泌肿瘤学会顾问委员会2022年会议共识报告:[18F]FDG PET/CT在神经内分泌肿瘤中的使用及感知效用
欧洲神经内分泌肿瘤学会顾问委员会2022年会议基于问卷(应答率70%)调查[18F]FDG PET/CT在神经内分泌肿瘤中的使用及决策效用,15条陈述中3条同意率超75%,4条超60%,多学科意见广泛支持FDG用于疾病生物学特征描述和治疗选择。
要点
- FDG在生长抑素受体PET/CT不匹配病灶中可考虑用于指导PRRT决策(80%同意)。
- NET G3若考虑治愈性手术(82%同意)或NEC术前(98%同意),FDG被认为有用。
- 既往G1-2 NET出现FDG阳性时,活检重新评估肿瘤分级获68%支持。
核心结论
- 多学科意见广泛支持[18F]FDG PET/CT用于描述神经内分泌肿瘤的疾病生物学特征并指导治疗选择,尽管许多情况下未达成完全共识。
研究设计与样本
- 基于问卷的共识报告,提交至欧洲神经内分泌肿瘤学会顾问委员会2022年11月会议参会者,应答率70%,对15条陈述进行同意度调查。
诊断标准与关键数值
- 15条陈述中3条同意率高于75%:不匹配病灶(诊断CT可检出但生长抑素受体PET/CT阴性或弱阳性)尤其考虑PRRT时FDG有用(80%);NET G3考虑治愈性手术时(82%);NEC治愈性手术前(98%)。
- 4条陈述同意率超过60%:NET G3考虑局部区域治疗时FDG使用(65%);NEC开始积极治疗前作为疗效评估基线(61%);既往G1-2 NET出现FDG阳性时活检重新评估肿瘤分级(68%);FDG阴性而生长抑素受体阳性残留病灶达到完全缓解后重新考虑PRRT(67%)。
- NET G3即使存在匹配病灶,FDG作为疗效评估基线获74%支持。
临床应用与阅片要点
- 对生长抑素受体PET/CT与诊断CT表现不匹配的病灶,可考虑加做FDG PET/CT以指导PRRT决策(80%同意)。
- NET G3考虑治愈性手术或NEC术前,FDG PET/CT被认为有用(同意率分别为82%和98%)。
- 既往G1-2 NET出现FDG阳性时,可考虑活检重新评估肿瘤分级(68%同意)。
局限性
- 许多情况下未达成完全共识。
- 临床可及性可能受报销缺乏或经验不足影响,需进一步研究解决。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Somatostatin receptor (SST) PET/CT is the gold standard for well-differentiated neuroendocrine tumours (NET) imaging. Higher grades of neuroendocrine neoplasms (NEN) show preferential [18F]FDG (FDG) uptake, and even low-grade NET may de-differentiate over time. FDG PET/CT's prognostic role is widely accepted; however, its impact on clinical decision-making remains controversial and its use varies widely. A questionnaire-based survey on FDG PET/CT use and perceived decision-making utility in NEN was submitted to the ENETS Advisory Board Meeting attendees (November 2022, response rate = 70%). In 3/15 statements, agreement was higher than 75%: (i) FDG was considered useful in NET, irrespective of grade, in case of mis-matched lesions (detectable on diagnostic CT but negative/faintly positive on SST PET/CT), especially if PRRT is contemplated (80%); (ii) in NET G3 if curative surgery is considered (82%); and (iii) in NEC prior to surgery with curative intent (98%). FDG use in NET G3, even in the presence of matched lesions, as a baseline for response assessment was favoured by 74%. Four statements obtained more than 60% consensus: (i) FDG use in NET G3 if locoregional therapy is considered (65%); (ii) in neuroendocrine carcinoma before initiating active therapy as a baseline for response assessment (61%); (iii) biopsy to re-assess tumour grade prior to a change in therapeutic management (68%) upon detection of FDG-positivity on the background of a prior G1-2 NET; (iv) 67% were in favour to reconsider PRRT to treat residual SST-positive lesions after achieving complete remission on FDG of the SST-negative disease component. Multidisciplinary opinion broadly supports the use of FDG PET/CT for characterisation of disease biology and to guide treatment selection across a range of indications, despite the lack of full consensus in many situations. This may reflect existing clinical access due to lack of reimbursement or experience with this investigation, which should be addressed by further research.
引用
- Ambrosini V, Caplin M, Castaño JP, et al. Use and perceived utility of [18 F]FDG PET/CT in neuroendocrine neoplasms: A consensus report from the European Neuroendocrine Tumor Society (ENETS) Advisory Board Meeting 2022. J Neuroendocrinol. 2023. PMID: 38097193. doi:10.1111/jne.13359
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。